SCHEMBL16626671

SCHEMBL16626671

CNCc1cn(S(=O)(=O)c2cccnc2)c2cc(Nc3ccc(Cl)cc3)ccc12

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 11/20 0.41
IDE P14735 1/20 0.39
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
TNNI3K Q59H18 2/20 0.36
FGFR4 P22455 1/20 0.35
NAMPT P43490 1/20 0.35
HTT P42858 1/20 0.35
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16618624 0.99 HTR6 (0.41) HTR6IDEPDE4APDE4BPDE4C
SCHEMBL16626412 0.95 HTR6 (0.38) HTR6IDE
Hydrochloric Acid SCHEMBL16618672 0.94 HTR6 (0.38) HTR6IDE
SCHEMBL16626438 0.94 HTR6 (0.39) HTR6IDEPDE4APDE4BPDE4C
SCHEMBL16626678 0.93 HTR6 (0.41) HTR6IDEPDE4APDE4BPDE4C
Hydrochloric Acid SCHEMBL16618754 0.93 HTR6 (0.38) HTR6IDEPDE4APDE4BPDE4C
SCHEMBL16626409 0.92 HTR6 (0.44) HTR6IDEFGFR4
Hydrochloric Acid SCHEMBL16619240 0.92 HTR6 (0.41) HTR6IDEPDE4APDE4BPDE4C
SCHEMBL16626415 0.91 CYP19A1 (0.43) HTR6IDEPDE4APDE4BPDE4C
Hydrochloric Acid SCHEMBL16618675 0.91 HTR6 (0.43) HTR6IDEFGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
CN-105612150-A Sulfonylindole derivatives and process for producing the same DAE WOONG PHARMA 2016-05-25 CN disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885IDE 2586/4885PDE4A 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.